BUSINESS● LOW2h ago · Oct 29, 2026, 6:59 AM
Vanda targets full-year 2026 total revenues greater than $240M as BYSANTI launch nears Q4
Seeking Alpha Tech · global
Vanda Pharmaceuticals is targeting total revenues exceeding $240 million for the full year 2026. This projection is made in anticipation of the BYSANTI product launch, which is nearing in the fourth quarter.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS35m agoETFs with the biggest Alphabet bets feel the heat as stock slidesSeeking Alpha TechBUSINESS38m agoGold in Ghana: After Damang, is Gold Fields at risk of being ousted from the Tarkwa mine?Jeune Afrique